The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | What role does TIGIT inhibition have in treating hepatocellular carcinoma?
Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the latest updates in anti-TIGIT therapies for patients with hepatocellular carcinoma (HCC). Findings from the Phase Ib/II MORPHEUS-Liver trial (NCT04524871) of tiragolumab with atezolizumab and bevacizumab demonstrated the potential clinical benefit of adding tiragolumab, a TIGIT inhibitor. The Phase III IMbrave152/SKYSCRAPER-14 trial (NCT05904886) will further assess this combination. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
